QQQ   351.05 (+0.76%)
AAPL   177.88 (+1.40%)
MSFT   332.03 (-0.26%)
META   265.68 (+1.39%)
GOOGL   124.21 (-0.32%)
AMZN   121.99 (+1.57%)
TSLA   199.54 (+3.30%)
NVDA   403.02 (+3.48%)
NIO   7.40 (-3.90%)
BABA   78.66 (-2.85%)
AMD   126.38 (-0.51%)
T   15.67 (+1.10%)
F   12.69 (+4.96%)
MU   72.80 (-1.53%)
CGC   0.87 (-0.40%)
GE   102.23 (-0.50%)
DIS   87.53 (-0.86%)
AMC   4.54 (-2.16%)
PFE   37.13 (-1.25%)
PYPL   61.26 (+1.73%)
NFLX   393.28 (+3.80%)
QQQ   351.05 (+0.76%)
AAPL   177.88 (+1.40%)
MSFT   332.03 (-0.26%)
META   265.68 (+1.39%)
GOOGL   124.21 (-0.32%)
AMZN   121.99 (+1.57%)
TSLA   199.54 (+3.30%)
NVDA   403.02 (+3.48%)
NIO   7.40 (-3.90%)
BABA   78.66 (-2.85%)
AMD   126.38 (-0.51%)
T   15.67 (+1.10%)
F   12.69 (+4.96%)
MU   72.80 (-1.53%)
CGC   0.87 (-0.40%)
GE   102.23 (-0.50%)
DIS   87.53 (-0.86%)
AMC   4.54 (-2.16%)
PFE   37.13 (-1.25%)
PYPL   61.26 (+1.73%)
NFLX   393.28 (+3.80%)
QQQ   351.05 (+0.76%)
AAPL   177.88 (+1.40%)
MSFT   332.03 (-0.26%)
META   265.68 (+1.39%)
GOOGL   124.21 (-0.32%)
AMZN   121.99 (+1.57%)
TSLA   199.54 (+3.30%)
NVDA   403.02 (+3.48%)
NIO   7.40 (-3.90%)
BABA   78.66 (-2.85%)
AMD   126.38 (-0.51%)
T   15.67 (+1.10%)
F   12.69 (+4.96%)
MU   72.80 (-1.53%)
CGC   0.87 (-0.40%)
GE   102.23 (-0.50%)
DIS   87.53 (-0.86%)
AMC   4.54 (-2.16%)
PFE   37.13 (-1.25%)
PYPL   61.26 (+1.73%)
NFLX   393.28 (+3.80%)
QQQ   351.05 (+0.76%)
AAPL   177.88 (+1.40%)
MSFT   332.03 (-0.26%)
META   265.68 (+1.39%)
GOOGL   124.21 (-0.32%)
AMZN   121.99 (+1.57%)
TSLA   199.54 (+3.30%)
NVDA   403.02 (+3.48%)
NIO   7.40 (-3.90%)
BABA   78.66 (-2.85%)
AMD   126.38 (-0.51%)
T   15.67 (+1.10%)
F   12.69 (+4.96%)
MU   72.80 (-1.53%)
CGC   0.87 (-0.40%)
GE   102.23 (-0.50%)
DIS   87.53 (-0.86%)
AMC   4.54 (-2.16%)
PFE   37.13 (-1.25%)
PYPL   61.26 (+1.73%)
NFLX   393.28 (+3.80%)
NASDAQ:ETON

Eton Pharmaceuticals (ETON) Stock Forecast, Price & News

$3.94
+0.08 (+2.07%)
(As of 12:52 PM ET)
Compare
Today's Range
$3.89
$3.96
50-Day Range
$3.40
$4.08
52-Week Range
$1.95
$4.25
Volume
17,665 shs
Average Volume
55,082 shs
Market Capitalization
$100.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Eton Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
153.8% Upside
$10.00 Price Target
Short Interest
Healthy
2.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Eton Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.32) to $0.15 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

619th out of 1,009 stocks

Pharmaceutical Preparations Industry

307th out of 494 stocks


ETON stock logo

About Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Receive ETON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ETON Stock News Headlines

The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
8-K: Eton Pharmaceuticals, Inc.
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Eton Pharmaceuticals (ETON) to Release Earnings on Thursday
Allergic Conjunctivitis Market Top Players by 2031
H.C. Wainwright Remains a Buy on Eton Pharmaceuticals (ETON)
Here's what Wall Street expects from Eton Pharmaceuticals's earnings
See More Headlines
Receive ETON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ETON Company Calendar

Last Earnings
3/16/2023
Today
5/30/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ETON
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+152.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-9,020,000.00
Pretax Margin
-26.05%

Debt

Sales & Book Value

Annual Sales
$24.38 million
Book Value
$0.52 per share

Miscellaneous

Free Float
22,966,000
Market Cap
$101.00 million
Optionable
Not Optionable
Beta
1.45

Key Executives

  • Sean E. BrynjelsenSean E. Brynjelsen
    President, Chief Executive Officer & Director
  • James R. Gruber
    Chief Financial Officer, Secretary & Treasurer
  • David Krempa
    Chief Business Officer
  • Kevin Guthrie
    Executive Vice President-Commercial Operations
  • Ingrid Hoos
    Senior Vice President-Regulatory Affairs













ETON Stock - Frequently Asked Questions

Should I buy or sell Eton Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ETON shares.
View ETON analyst ratings
or view top-rated stocks.

What is Eton Pharmaceuticals' stock price forecast for 2023?

1 brokerages have issued 12-month price targets for Eton Pharmaceuticals' stock. Their ETON share price forecasts range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 152.5% from the stock's current price.
View analysts price targets for ETON
or view top-rated stocks among Wall Street analysts.

How have ETON shares performed in 2023?

Eton Pharmaceuticals' stock was trading at $2.82 at the beginning of the year. Since then, ETON stock has increased by 40.4% and is now trading at $3.96.
View the best growth stocks for 2023 here
.

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 530,400 shares, a decline of 9.7% from the April 30th total of 587,500 shares. Based on an average trading volume of 47,900 shares, the short-interest ratio is presently 11.1 days. Approximately 2.4% of the company's shares are sold short.
View Eton Pharmaceuticals' Short Interest
.

When is Eton Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ETON earnings forecast
.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its quarterly earnings results on Thursday, March, 16th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. The business earned $8.50 million during the quarter, compared to analyst estimates of $9.10 million. Eton Pharmaceuticals had a negative net margin of 26.05% and a negative trailing twelve-month return on equity of 52.12%.

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Westside Investment Management Inc. (2.03%), Acuitas Investments LLC (1.84%), Stratos Wealth Partners LTD. (0.36%), Lido Advisors LLC (0.17%), Blair William & Co. IL (0.14%) and Renaissance Technologies LLC (0.05%). Insiders that own company stock include Harrow Health, Inc, Opaleye Management Inc, Pharmaceutical Co Ltd Takeda and Sean Brynjelsen.
View institutional ownership trends
.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $3.96.

How much money does Eton Pharmaceuticals make?

Eton Pharmaceuticals (NASDAQ:ETON) has a market capitalization of $101.00 million and generates $24.38 million in revenue each year. The company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The official website for the company is www.etonpharma.com. The company can be reached via phone at (847) 787-7361 or via email at investorrelations@etonpharma.com.

This page (NASDAQ:ETON) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -